Impact Of Muscle Vibration On Gait Control

Description

This is a single-site interventional open label pilot study of a non-significant risk medical device on patients with defined peripheral neuropathy secondary to chemotherapy (N=10). Patients who have received chemotherapy and have evidence of neuropathy will be seen at MD Anderson. Their severity of neuropathy will be documented and assessed by physical therapy, occupational therapy and based on self-reported activities of daily living (ADL) impairment.

Conditions

Muscle

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a single-site interventional open label pilot study of a non-significant risk medical device on patients with defined peripheral neuropathy secondary to chemotherapy (N=10). Patients who have received chemotherapy and have evidence of neuropathy will be seen at MD Anderson. Their severity of neuropathy will be documented and assessed by physical therapy, occupational therapy and based on self-reported activities of daily living (ADL) impairment.

Impact Of Muscle Vibration On Gait Control

Impact Of Muscle Vibration On Gait Control

Condition
Muscle
Intervention / Treatment

-

Contacts and Locations

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subjects between the ages of 6 and 39 years.
  • * Study subjects, or their parent/legal guardian for subjects \<18 years, must be able to understand the purpose and risks of the study and to provide signed and dated informed consent and authorization to use confidential health information in accordance with national and local subject privacy regulations.
  • * History of any type of cancer-
  • * Diagnosed with peripheral neuropathy-associated gait dysfunction as defined by the treating physician.
  • * Able (in the Investigators estimation) and willing to comply with all study requirements.
  • * Subjects must be able to walk; assistance of a walker or similar support apparatus is allowed.
  • * Patients with ankle foot orthosis (AFOs) are allowed but will need to be removed prior to testing.
  • * Participants with amputations, prosthetics, congenital malformations or any severe lower extremity deformities affecting gait before trials.
  • * Abnormalities of the lower extremities as determined by the investigator.
  • * Unstable participants or participants with hypotension (systolic blood pressure \<90 and diastolic blood pressure \< 60mmHg).
  • * Any other significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  • * Other unspecified reasons that, in the opinion of the Investigator make the subject unsuitable for enrolment
  • * Pregnant women
  • * Children \<15 years old
  • * Blind

Ages Eligible for Study

6 Years to 39 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

David McCall, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2025-12-31